This article discusses the risk and opportunities of six major constituents of PJP ETF: Pfizer, Amgen, Gilead, AbbVie, BMY, ...

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results.

This issue highlights a broader concern regarding medication coverage and affordable health care. It underscores the critical ...

U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

A review found half of the drugs studied had price increases based on new evidence of benefits, while the other half did not.